TNF and multiple sclerosis: The risk of demyelination associated with the use of anti-TNF was raised by a drug, no longer available, called Lenercept, which would have been indicated for multiple sclerosis (MS), but led to its exacerbation, and Efalizumab, a medication used for psoriasis that was withdrawn from the market later due to cases of progressive leukoencephalopathy.